Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment.
Citation: Clinical Lung Cancer. 23(6):542-546, 2022 09.PMID: 35701321Institution: MedStar Washington Hospital CenterDepartment: DermatologyForm of publication: Journal ArticleMedline article type(s): Case ReportsSubject headings: *Carcinoma, Non-Small-Cell Lung | *Drug-Related Side Effects and Adverse Reactions | *Lung Neoplasms | *Sarcoidosis | *Sarcoidosis, Pulmonary | Antibodies, Monoclonal, Humanized | Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy] | Humans | Lung Neoplasms/di [Diagnosis] | Sarcoidosis, Pulmonary/ci [Chemically Induced] | Sarcoidosis, Pulmonary/di [Diagnosis] | Sarcoidosis/ci [Chemically Induced] | Sarcoidosis/di [Diagnosis]Year: 2022ISSN:- 1525-7304
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 35701321 | Available | 35701321 |
Immune checkpoint inhibitor (ICI) therapy has reshaped the treatment landscape in many cancers including non-small cell lung cancer (NSCLC). ICI-therapy can lead to a diverse array of immune-related adverse effects (irAEs), and prompt recognition and management are key to successful treatment. With wide-spread use of ICI therapy in clinical practice, rare irAEs are being increasingly recognized. This report documents a patient with advanced NSCLC who developed pembrolizumab-associated sarcoidosis with multiorgan involvement. Multidisciplinary management led to timely diagnosis and treatment, leading to improvement in symptoms. This case raises awareness of sarcoidosis as a rare side effect of pembrolizumab. Copyright © 2022. Published by Elsevier Inc.
English